Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moxifloxacin + dexamethasone is a fixed-dose combination ophthalmic medication used primarily for the treatment of bacterial eye infections and associated inflammation. It combines moxifloxacin, a fourth-generation fluoroquinolone antibiotic, with dexamethasone, a potent synthetic glucocorticoid corticosteroid. Moxifloxacin acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair in bacteria. This results in bactericidal activity against a broad spectrum of Gram-positive and Gram-negative organisms[6][8]. Dexamethasone exerts anti-inflammatory effects by binding to the glucocorticoid receptor and modulating gene expression to suppress pro-inflammatory mediators such as prostaglandins[3][6]. The combination is indicated for use in ocular conditions where both infection and inflammation are present or suspected[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moxifloxacin + dexamethasone.